Swiss biopharma GeNeuro has secured the exclusive worldwide license to the clinical development program for a pHERV-K Env antibody after preclinical results showed its potential to treat amyotrophic lateral sclerosis (ALS). The company exercised its option for the rights to the investigational therapy under the terms of a January 2017…
GeNeuro Secures Rights to Potential ALS Therapy After Promising Preclinical Studies With NINDS
Voyager Therapeutics’ experimental therapy VY-SOD102 shows promise for treating patients with familial amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene, according to results in animal models. The preclinical data were presented at the Congress of the European Society of Gene and Cell Therapy…
My (Ice) Bucket List
“… And up through the ground come a bubblin’ crude.” Like Jed Clampett of “Beverly Hillbillies” fame, the ALS Association in 2014 found itself in the unexpected circumstance of commanding assets beyond its wildest dreams. The national display of generosity, hope, and compassion dubbed the ice…
Tiglutik, an oral suspension of riluzole, is now available as a treatment for amyotrophic lateral sclerosis (ALS) in the U.S., ITF Pharma, the therapy’s developer and a subsidiary of Italfarmaco, recently announced. Rilutek (riluzole, marketed by Sanofi), has been available in the U.S. as 50 mg tablets…
The Art of ALS Adaptability
Life with ALS often feels like a crash course in adaptability but being adaptable doesn’t come naturally for many of us. However, whether you’re the patient, caregiver, or a family member, I believe you can learn how. Read on and let’s get started. In my pre-ALS life…
SOD1 gene mutations can contribute differently to the degenerative process of nerve cells involved in the progression of amyotrophic lateral sclerosis (ALS), newly developed worm models of the disease reveal. This finding was reported in the study, “Single copy/knock-in models…
One of the most awful parts of my diagnosis was the loss of my career. Teaching was more than a job to me — it was part of my identity. I wish I knew then that my loss wouldn’t be as total as I had imagined. Don’t give…
Chip technology — much like an organ-on-a-chip that can simulate the workings of tissue or organs — was used to recreate amyotrophic lateral sclerosis (ALS), allowing researchers to identify two treatments for blood cancers — rapamycin plus bosutinib — as a possible ALS combination therapy. The study, “Microphysiological 3D model…
Researchers have discovered that mast cells and neutrophils — two types of immune cells — are involved in the degeneration of peripheral motor nerve cells and progression of amyotrophic lateral sclerosis (ALS). These findings also clarify why masitinib — an investigational therapy for ALS that targets mast cells…
The Muscular Dystrophy Association (MDA) will host its 18th annual Wings Over Wall Street benefit Oct. 17 to raise funds for amyotrophic lateral sclerosis (ALS) research with the ultimate goal of defeating the disease, the nonprofit announced. Presented by Investors Exchange and emceed by ABC affiliate…
Recent Posts
- Actor Eric Dane honored for bringing visibility and hope to the ALS fight
- New ALS drug neflamapimod chosen for UK platform study
- Scientists find promising 3 drug combo for sporadic ALS using new models
- Small adjustments to a wheelchair can greatly improve comfort
- How ALS patients can show their stripes for Rare Disease Month